Holen Sie sich die Stockscreener-App
3.04
3.05%
0.09
Schlusskurs vom Vortag:
$2.95
Offen:
$2.96
24-Stunden-Volumen:
25,968
Relative Volume:
0.41
Marktkapitalisierung:
$12.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.79M
KGV:
-0.4916
EPS:
-6.1838
Netto-Cashflow:
$-23.12M
1W Leistung:
+10.14%
1M Leistung:
-5.00%
6M Leistung:
-38.96%
1J Leistung:
+935.42%
1-Tages-Spanne:
$2.94
$3.06
1-Wochen-Bereich:
$2.67
$3.06
52-Wochen-Spanne:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.04 | 12.51M | 0 | -21.79M | -23.12M | -6.1838 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Cellectar Biosciences (CLRB) Begins Phase 1b Trial for Triple Ne - GuruFocus
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Triple Negative Breast Cancer - National Today
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer - National Today
Cellectar enrolls first patient in phase 1b cancer trial By Investing.com - Investing.com India
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) - The Manila Times
First patient joins Cellectar study for hard-to-treat breast cancer - Stock Titan
Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer - Intellectia AI
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Aug Mood: Can Cellectar Biosciences Inc weather a recession2026 PostEarnings & Entry Point Strategy Guides - baoquankhu1.vn
CEO Moves: Is Cellectar Biosciences Inc a top pick in the sectorIPO Watch & Weekly Top Performers Watchlists - baoquankhu1.vn
Growth Value: Will Cellectar Biosciences Inc stock benefit from M AQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Trading Action: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Buybacks Report: How does Cellectar Biosciences Inc compare to its peersQuarterly Portfolio Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Aug Technicals: Will Cellectar Biosciences Inc outperform during market ralliesOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Smart Money: Is Cellectar Biosciences Inc a top pick in the sectorQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
VIX Spike: Can Cellectar Biosciences Inc weather a recessionTrade Risk Assessment & Community Verified Trade Alerts - baoquankhu1.vn
What drives Cellectar Biosciences Incs stock price2026 Risk Factors & Weekly High Potential Stock Alerts - baoquankhu1.vn
ETF Watch: Will WASH benefit from geopolitical trendsShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Big Money Moves: How cyclical is Cellectar Biosciences Incs revenue streamTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
If You Invested $1,000 in Cellectar Biosciences Inc (CLRB) - Stock Titan
Meme Stocks: Can Cellectar Biosciences Inc disrupt its industryMarket Trend Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Aug Patterns: How does Cellectar Biosciences Inc compare to its peers2026 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Layoff Watch: Will Cellectar Biosciences Inc stock benefit from M A2026 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Trading Recap: Can Cellectar Biosciences Inc weather a recessionWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
Risk Report: Does Cellectar Biosciences Inc have a sustainable dividendTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Rate Cut: Can Cellectar Biosciences Inc weather a recessionMarket Growth Report & Short-Term Trading Alerts - baoquankhu1.vn
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Buy at Maxim Group - Defense World
CLRB: Maxim Group Upgrades Cellectar Biosciences to Buy with $10 Target | CLRB Stock News - GuruFocus
Ideas Watch: Can Cellectar Biosciences Inc weather a recessionPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences Charts Risky Path to Approvals - TipRanks
Quarterly Trades: Does Cellectar Biosciences Inc have a sustainable dividendJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Can Cellectar Biosciences Inc weather a recessionWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Should you sell your Cellectar Biosciences stock? - Cantech Letter
Death Cross: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cellectar (CLRB) Marks Significant Achievements in 2025 - GuruFocus
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cellectar (CLRB) Q4 2025 Earnings Call Transcript - The Globe and Mail
CLRB: Advanced late-stage pipeline, improved financials, and set up for major regulatory milestones in 2026 - TradingView
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Investing News Network
CLRB: Advanced regulatory progress, reduced losses, and extended cash runway position for key 2026 milestones - TradingView
Cellectar Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows - AlphaStreet News
CLRB: Net loss narrowed to $21.8M in 2025, but new funding is needed beyond Q3 2026 - TradingView
CLRB: Net loss narrowed as pipeline advanced toward key regulatory and clinical milestones - TradingView
Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView
Cellectar (NASDAQ: CLRB) halves 2025 loss while pushing key cancer drugs - Stock Titan
Iopofosine progress at Cellectar (NASDAQ: CLRB) with pivotal WM data and FDA path - Stock Titan
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):